The study will be a double-blind, randomized, placebo-controlled, single-center, 2 treatment,
3--way crossover. Subjects will be randomly allocated to a treatment sequence - AAB, ABA or
BAA. The two treatments will be:
- Treatment A: 500 mg nicotinic acid (Niacor(R))
- Treatment B: Niacor(R) Placebo
Each trial period will last one day, there will be a wash-out period of at least 2 days
between each trial period. Five to seven days after study day 1 of trial period 3 there will
be a final safety examination.